-
2
-
-
8744240727
-
Determinants of quality of life in patients with psoriasis: A study from the US population
-
Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-8.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 704-708
-
-
Gelfand, J.M.1
Feldman, S.R.2
Stern, R.S.3
-
3
-
-
53349119980
-
The impact of psoriasis on health care costs and patient work loss
-
Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008;59:772-80.
-
(2008)
J Am Acad Dermatol
, vol.59
, pp. 772-780
-
-
Fowler, J.F.1
Duh, M.S.2
Rovba, L.3
-
4
-
-
79960593968
-
What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010
-
quiz 588-9
-
Foulkes AC, Grindlay DJ, Griffiths CE, et al. What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. Clin Exp Dermatol 2011;36:585-9; quiz 588-9.
-
(2011)
Clin Exp Dermatol
, vol.36
, pp. 585-589
-
-
Foulkes, A.C.1
Grindlay, D.J.2
Griffiths, C.E.3
-
5
-
-
23644442757
-
Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis
-
Malhotra S, Bansal D, Shafiq N, et al. Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis. Expert Opin Pharmacother 2005;6:1455-61.
-
(2005)
Expert Opin Pharmacother
, vol.6
, pp. 1455-1461
-
-
Malhotra, S.1
Bansal, D.2
Shafiq, N.3
-
7
-
-
0018099294
-
Severe psoriasis - Oral therapy with a new retinoid
-
Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
-
(1978)
Dermatologica
, vol.157
, pp. 238-244
-
-
Fredriksson, T.1
Pettersson, U.2
-
8
-
-
34248335482
-
New method being developed for assessing psoriasis. NPF psoriasis score - Your input needed
-
Krueger G. New method being developed for assessing psoriasis. NPF psoriasis score - your input needed. National Psoriasis Foundation Psoriasis Forum 1999;5:1-5.
-
(1999)
National Psoriasis Foundation Psoriasis Forum
, vol.5
, pp. 1-5
-
-
Krueger, G.1
-
9
-
-
4644309388
-
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment
-
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563-9.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 563-569
-
-
Langley, R.G.1
Ellis, C.N.2
-
10
-
-
77749326687
-
Evidence-based recommendations to assess psoriasis severity: Systematic literature review and expert opinion of a panel of dermatologists
-
Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010;24 Suppl 2:2-9.
-
(2010)
J Eur Acad Dermatol Venereol
, vol.24
, Issue.SUPPL. 2
, pp. 2-9
-
-
Paul, C.1
Gourraud, P.A.2
Bronsard, V.3
-
11
-
-
19244365650
-
Thiazolidinediones
-
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Järvinen, H.1
-
13
-
-
0031003829
-
Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes
-
Morikang E, Benson SC, Kurtz TW, et al. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997;10:440-6.
-
(1997)
Am J Hypertens
, vol.10
, pp. 440-446
-
-
Morikang, E.1
Benson, S.C.2
Kurtz, T.W.3
-
14
-
-
0031886864
-
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
-
Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
-
(1998)
Nature
, vol.391
, pp. 79-82
-
-
Ricote, M.1
Li, A.C.2
Willson, T.M.3
-
15
-
-
0034030527
-
Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation
-
Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000;136:609-16.
-
(2000)
Arch Dermatol
, vol.136
, pp. 609-616
-
-
Ellis, C.N.1
Varani, J.2
Fisher, G.J.3
-
16
-
-
0032742408
-
Pharmacological peroxisome proliferator-activated receptorgamma ligands: Emerging clinical indications beyond diabetes
-
Pershadsingh HA. Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes. Expert Opin Investig Drugs 1999;8:1859-72.
-
(1999)
Expert Opin Investig Drugs
, vol.8
, pp. 1859-1872
-
-
Pershadsingh, H.A.1
-
17
-
-
13244286538
-
Pioglitazone: A promising therapy for psoriasis
-
Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol 2005;152:189-91.
-
(2005)
Br J Dermatol
, vol.152
, pp. 189-191
-
-
Robertshaw, H.1
Friedmann, P.S.2
-
18
-
-
33750135442
-
Thiazolidinediones: Potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
-
Varani J, Bhagavathula N, Ellis CN, et al. Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. Expert Opin Investig Drugs 2006;15:1453-68.
-
(2006)
Expert Opin Investig Drugs
, vol.15
, pp. 1453-1468
-
-
Varani, J.1
Bhagavathula, N.2
Ellis, C.N.3
-
19
-
-
39149102510
-
Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study
-
Brauchli YB, Jick SS, Curtin F, et al. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol 2008;58:421-9.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 421-429
-
-
Brauchli, Y.B.1
Jick, S.S.2
Curtin, F.3
-
20
-
-
12344282955
-
Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study
-
Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 2005;44:126-9.
-
(2005)
Rheumatology (Oxford)
, vol.44
, pp. 126-129
-
-
Bongartz, T.1
Coras, B.2
Vogt, T.3
-
22
-
-
17444404606
-
Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6)
-
Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005;44:328-33.
-
(2005)
Int J Dermatol
, vol.44
, pp. 328-333
-
-
Shafiq, N.1
Malhotra, S.2
Pandhi, P.3
-
23
-
-
65349091931
-
Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial
-
Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009;145:387-93.
-
(2009)
Arch Dermatol
, vol.145
, pp. 387-393
-
-
Mittal, R.1
Malhotra, S.2
Pandhi, P.3
-
25
-
-
34250633274
-
Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone
-
Ellis CN, Barker JN, Haig AE, et al. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 2007;8:93-102.
-
(2007)
Am J Clin Dermatol
, vol.8
, pp. 93-102
-
-
Ellis, C.N.1
Barker, J.N.2
Haig, A.E.3
-
27
-
-
33748935095
-
The case of the misleading funnel plot
-
Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ 2006;333:597-600.
-
(2006)
BMJ
, vol.333
, pp. 597-600
-
-
Lau, J.1
Ioannidis, J.P.2
Terrin, N.3
-
28
-
-
2542445474
-
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
-
Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.
-
(2004)
J Am Acad Dermatol
, vol.50
, pp. 859-866
-
-
Carlin, C.S.1
Feldman, S.R.2
Krueger, J.G.3
-
29
-
-
0042625001
-
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
-
Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
-
(2003)
N Engl J Med
, vol.349
, pp. 658-665
-
-
Heydendael, V.M.1
Spuls, P.I.2
Opmeer, B.C.3
-
30
-
-
0022461338
-
Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes
-
Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
-
(1986)
Dermatologica
, vol.172
, pp. 298-304
-
-
Lindegård, B.1
-
32
-
-
0038116697
-
Lipid profile, insulin secretion, and insulin sensitivity in psoriasis
-
Reynoso-von Drateln C, Martínez-Abundis E, Balcázar- Muñoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003;48:882-5.
-
(2003)
J Am Acad Dermatol
, vol.48
, pp. 882-885
-
-
Reynoso-von Drateln, C.1
Martínez-Abundis, E.2
Balcázar- Muñoz, B.R.3
-
33
-
-
33751181855
-
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
-
Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
-
(2006)
Arch Dermatol Res
, vol.298
, pp. 321-328
-
-
Sommer, D.M.1
Jenisch, S.2
Suchan, M.3
-
34
-
-
33749662118
-
Prevalence of cardiovascular risk factors in patients with psoriasis
-
Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
-
(2006)
J Am Acad Dermatol
, vol.55
, pp. 829-835
-
-
Neimann, A.L.1
Shin, D.B.2
Wang, X.3
-
36
-
-
0034604248
-
Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
-
Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
-
(2000)
Circulation
, vol.102
, pp. 42-47
-
-
Festa, A.1
D'Agostino Jr., R.2
Howard, G.3
-
37
-
-
3042741188
-
The inflammatory response in mild and in severe psoriasis
-
Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917-28.
-
(2004)
Br J Dermatol
, vol.150
, pp. 917-928
-
-
Rocha-Pereira, P.1
Santos-Silva, A.2
Rebelo, I.3
-
38
-
-
1442275317
-
Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes
-
Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
-
(2004)
Diabetes Care
, vol.27
, pp. 813-823
-
-
Pickup, J.C.1
-
39
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
40
-
-
77954988618
-
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
-
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18.
-
(2010)
JAMA
, vol.304
, pp. 411-418
-
-
Graham, D.J.1
Ouellet-Hellstrom, R.2
Macurdy, T.E.3
|